A novel rpa-crispr/cas12a platform enables ultrasensitive detection of the kras g12c mutation, suggesting improved diagnostic capabilities.
Sticky end-driven PAM-free RPA-CRISPR/Cas12a fluorescence sensing platform for the ultrasensitive detection of KRAS G12C mutation.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: